| 利用者成果(英) |
|
19799
Hata T, Uematsu Y, Sugita A, Adachi H, Kato S, Hirate M, Ishikura KI, Kaku A, Ohara H, Kojima N, Takahashi T, Kurokawa T.
A Potent Neutralizing Monoclonal Antibody to Human Growth Hormone Suppresses Insulin-Like Growth Factor-1 in female Rats
Endocrinology
2024
Mar 19:bqae033
PubMed ID: 38500360
DOI: 10.1210/endocr/bqae033
|
|
21617
Okura Y, Ikawa-Teranishi Y, Mizoroki A, Takahashi N, Tsushima T, Irie M, Harfuddin Z, Miura-Okuda M, Ito S, Nakamura G, Takesue H, Ozono Y, Nishihara M, Yamada K, Gan SW, Hayasaka A, Ishii S, Wakabayashi T, Muraoka M, Nagaya N, Hino H, Nemoto T, Kuramochi T, Torizawa T, Shimada H, Kitazawa T, Okazaki M, Nezu J, Sollid LM, Igawa T.
Characterizations of a neutralizing antibody broadly reactive to multiple gluten peptide:HLA-DQ2.5 complexes in the context of celiac disease.
Nat Commun
2024
14(1):8502
PubMed ID: 38135691
DOI: 10.1038/s41467-023-44083-4
|
|
21641
Umene K, Kawahara M.
Synthetic receptor scaffolds significantly affect the efficiency of cell fate signals.
Sci Rep
2024
14(1):5801
PubMed ID: 38461201
DOI: 10.1038/s41598-024-56612-2
|
|
19719
Garbers C, Rose-John S.
Dissecting Interleukin-6 Classic and Trans-signaling in Inflammation and Cancer
Methods Mol Biol
2023
2691:207-224
PubMed ID: 37355548
DOI: 10.1007/978-1-0716-3331-1_16
|
|
19751
Koga T, Soh J, Hamada A, Miyano Y, Fujino T, Obata K, Ohara S, Nishino M, Chiba M, Shimoji M, Takemoto T, Suda K, Sakai K, Sato H, Mitsudomi T.
Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing
JTO Clin Res Rep
2023
4(9):100554
PubMed ID: 37681218
DOI: 10.1016/j.jtocrr.2023.100554
|
|
19977
Ochi N, Takeyama M, Miyake N, Fuchigami M, Yamane H, Fukazawa T, Nagasaki Y, Kawahara T, Nakanishi H, Takigawa N.
The complexity of EGFR exon 19 deletion and L858R mutant cells as assessed by proteomics, transcriptomics, and metabolomics
Exp Cell Res
2023
424(1):113503
PubMed ID: 36731710
DOI: 10.1016/j.yexcr.2023.113503
|
|
21235
Lim SM, Fujino T, Kim C, Lee G, Lee YH, Kim DW, Ahn JS, Mitsudomi T, Jin T, Lee SY.
BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.
Clin Cancer Res
2023
PubMed ID: 37249619
DOI: 10.1158/1078-0432.CCR-22-3901
|
|
21407
Umene K, Nagamune T, Kawahara M.
Phenotypic screening of signaling motifs that efficiently induce cell proliferation.
Sci Rep
2023
13(1):15639
PubMed ID: 37730760
DOI: 10.1038/s41598-023-42378-6
|
|
17495
Sakashita T, Yanagitani N, Koike S, Low SK, Takagi S, Baba S, Takeuchi K, Nishio M, Fujita N, Katayama R.
Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer
Cancer Sci
2022
113(11):3888-3900
PubMed ID: 35950895
DOI: 10.1111/cas.15529
|
|
17578
Mitani Y, Ohashi S, Kikuchi O, Nakai Y, Ida T, Mizumoto A, Yamamoto Y, Saito T, Kataoka S, Matsubara J, Yamada A, Kanai M, Matsumoto S, Sakai H, Yoshikawa K, Nakamura E, Muto M.
HER2 G776S mutation promotes oncogenic potential in colorectal cancer cells when accompanied by loss of APC function
Sci Rep
2022
12(1):9213
PubMed ID: 35654814
DOI: 10.1038/s41598-022-13189-y
|
|
17697
Furugaki K, Harada N, Yoshimura Y.
Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells
Anticancer Drugs
2022
33(2):124-131
PubMed ID: 34520436
DOI: 10.1097/CAD.0000000000001249
|
|
20414
Miyauchi M, Sasaki K, Kagoya Y, Taoka K, Masamoto Y, Yamazaki S, Arai S, Mizuno H, Kurokawa M.
CAMK2G is identified as a novel therapeutic target for myelofibrosis.
Blood Adv
2022
PubMed ID: 34521112
DOI: 10.1182/bloodadvances.2020003303
|
|
16227
Kazuya Sumi, Kenji Tago, Yosuke Nakazawa, Kyoko Takahashi, Tomoyuki Ohe, Tadahiko Mashino, Megumi Funakoshi-Tago
Novel Mechanism by a Bis-Pyridinium Fullerene Derivative to Induce Apoptosis by Enhancing the MEK-ERK Pathway in a Reactive Oxygen Species-Independent Manner in BCR-ABL-Positive Chronic Myeloid Leukemia-Derived K562 Cells
Int J Mol Sci
2022
23(2):749
PubMed ID: 35054935
DOI: 10.3390/ijms23020749
|
|
16427
Koga T, Suda K, Mitsudomi T.
Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer
Cancer Sci
2022
113(3):815-827
PubMed ID: 34997674
DOI: 10.1111/cas.15263
|
|
20617
Miura T, Kawano M, Takahashi K, Yuasa N, Habu M, Kimura F, Imamura T, Nakayama F.
High-Sulfated Hyaluronic Acid Ameliorates Radiation-Induced Intestinal Damage Without Blood Anticoagulation.
Adv Radiat Oncol
2022
7(3):100900
PubMed ID: 35295873
DOI: 10.1016/j.adro.2022.100900
|
|
20731
Shiba-Ishii A, Johnson TW, Dagogo-Jack I, Mino-Kenudson M, Johnson TR, Wei P, Weinrich SL, McTigue MA, Walcott MA, Nguyen-Phuong L, Dionne K, Acker A, Kiedrowski LA, Do A, Peterson JL, Barth JL, Yeap BY, Gainor JF, Lin JJ, Yoda S, Hata AN.
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.
Nat Cancer
2022
PubMed ID: 35726063
DOI: 10.1038/s43018-022-00399-6
|
|
16770
Fujino T, Suda K, Koga T, Hamada A, Ohara S, Chiba M, Shimoji M, Takemoto T, Soh J, Mitsudomi T.
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
J Hematol Oncol
2022
15(1):79
PubMed ID: 35690785
DOI: 10.1186/s13045-022-01299-z
|
|
20905
Kwak C, Park C, Ko M, Im CY, Moon H, Park YH, Kim SY, Lee S, Kang MG, Kwon HJ, Hong E, Seo JK, Rhee HW.
Identification of proteomic landscape of drug-binding proteins in live cells by proximity-dependent target ID.
Cell Chem Biol
2022
PubMed ID: 36272407
DOI: 10.1016/j.chembiol.2022.10.001
|
|
20910
Kimura Y, Kashima D, Kawahara M.
A growth-based platform for detecting domain-peptide interactions in the cytoplasm of mammalian cells.
Sci Rep
2022
12(1):18028
PubMed ID: 36302843
DOI: 10.1038/s41598-022-22770-4
|
|
20920
Okuda H, Miyamoto R, Takahashi S, Kawamura T, Ichikawa J, Harada I, Tamura T, Yokoyama A.
RNA-binding proteins of KHDRBS and IGF2BP families control the oncogenic activity of MLL-AF4.
Nat Commun
2022
13(1):6688
PubMed ID: 36335100
DOI: 10.1038/s41467-022-34558-1
|
|
20930
Mendivil-Perez M, Jimenez-Del-Rio M, Velez-Pardo C.
TPEN/TPGS (T2) combo dramatically reduces Philadelphia chromosome-positive pro-lymphoblastic B leukemia in BALB/c mice.
Med Oncol
2022
40(1):15
PubMed ID: 36352172
DOI: 10.1007/s12032-022-01873-y
|
|
12148
David Koschut, Debleena Ray, Zhenhua Li, Emanuela Giarin, Jürgen Groet, , Ivan Alić, Shirley Kow-Yin Kham, , Wee Joo Chng, Hany Ariffin, , David M. Weinstock, , Allen Eng-Juh Yeoh, , Giuseppe Basso, , Dean Nižetić
RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia
Oncogene
2021
40(4):746-762
PubMed ID: 33247204
DOI: 10.1038/s41388-020-01567-7
|
|
20107
Jia W, Kong L, Kidoya H, Naito H, Muramatsu F, Hayashi Y, Hsieh HY, Yamakawa D, Hsu DK, Liu FT, Takakura N.
Indispensable role of Galectin-3 in promoting quiescence of hematopoietic stem cells.
Nat Commun
2021
12(1):2118
PubMed ID: 33837181
DOI: 10.1038/s41467-021-22346-2
|
|
20184
Kashima D, Kawahara M.
Evolution of KIPPIS as a versatile platform for evaluating intracellularly functional peptide aptamers.
Sci Rep
2021
11(1):11758
PubMed ID: 34083659
DOI: 10.1038/s41598-021-91287-z
|
|
20317
Kongkrongtong T, Zhang R, Kawahara M.
Rational design of heterodimeric receptors capable of activating target signaling molecules.
Sci Rep
2021
11(1):16809
PubMed ID: 34413422
DOI: 10.1038/s41598-021-96396-3
|
|
15885
Ryo Nagai, Takeru Ebihara, Kohei Kakino, Akitsu Masuda, Jian Xu, Kosuke Minamihata, Noriho Kamiya, Tatphon Kongkrongtong, Masahiro Kawahara, Hiroaki Mon, Tsuguru Fujii, Takahiro Kusakabe, Jae Man Lee
Production of an active Mus musculus IL-3 using updated silkworm-based baculovirus expression vector system
Journal of Asia-Pacific Entomology
2021
24:544-549
DOI: 10.1016/j.aspen.2021.04.011
|
|
16098
Tanaka N, Lin JJ, Li C, Ryan MB, Zhang J, Kiedrowski LA, Michel AG, Syed MU, Fella KA, Sakhi M, Baiev I, Juric D, Gainor JF, Klempner SJ, Lennerz JK, Siravegna G, Bar-Peled L, Hata AN, Heist RS, Corcoran RB.
Clinical Acquired Resistance to KRAS G12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation
Cancer Discov
2021
11(8):1913-1922
PubMed ID: 33824136
DOI: 10.1158/2159-8290.CD-21-0365
|
|
16117
Koga T, Suda K, Fujino T, Ohara S, Hamada A, Nishino M, Chiba M, Shimoji M, Takemoto T, Arita T, Gmachl M, Hofmann MH, Soh J, Mitsudomi T
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments
J Thorac Oncol
2021
16(8):1321-1332
PubMed ID: 33971321
DOI: 10.1016/j.jtho.2021.04.015
|
|
16769
Koya Y, Nara H, Yagi S, Ueno C, Kamohara M.
An engineered tetra-valent antibody fully activates the Tie2 receptor with comparable potency to its natural ligand angiopoietin-1
Sci Rep
2021
11(1):14021
PubMed ID: 34234265
DOI: 10.1038/s41598-021-93660-4
|
|
16774
Koga T, Suda K, Nishino M, Fujino T, Ohara S, Hamada A, Soh J, Tirunagaru V, Vellanki A, Doebele RC, Mitsudomi T.
Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study
Transl Lung Cancer Res
2021
10(8):3659-3670
PubMed ID: 34584864
DOI: 10.21037/tlcr-21-216
|
|
11561
Yamada R, Fukumoto R, Noyama C, Fujisawa A, Oka S, Imamura T.
An epidermis-permeable dipeptide is a potential cosmetic ingredient with partial agonist/antagonist activity toward fibroblast growth factor receptors.
J Cosmet Dermatol
2020
19(2):477-484
PubMed ID: 31099492
DOI: 10.1111/jocd.12997
|
|
12115
Hirai N, Sasaki T, Okumura S, Minami Y, Chiba S, Ohsaki Y.
Monomerization of ALK Fusion Proteins as a Therapeutic Strategy in ALK-Rearranged Non-small Cell Lung Cancers.
Front Oncol
2020
PubMed ID: 32300555
DOI: 10.3389/fonc.2020.00419
|
|
13011
Tanaka H, Negoro K, Koike T, Tsukamoto I, Yokoyama K, Maeda J, Inagaki Y, Shimoshige Y, Ino K, Ishizu K, Takahashi T.
Discovery and structure-activity relationships study of positive allosteric modulators of the M3 muscarinic acetylcholine receptor.
Bioorg Med Chem
2020
PubMed ID: 32386953
DOI: 10.1016/j.bmc.2020.115531
|
|
13901
Yamahira S, Heike Y.
Facile Fabrication of Thin-Bottom Round-Well Plates Using the Deformation of PDMS Molds and Their Application for Single-Cell PCR
Micromachines (Basel)
2020
11(8):748
PubMed ID: 32751967
DOI: 10.3390/mi11080748
|
|
11428
Kang JH, Miettinen TP, Chen L, Olcum S, Katsikis G, Doyle PS, Manalis SR.
Noninvasive monitoring of single-cell mechanics by acoustic scattering.
Nat. Methods
2019
PubMed ID: 30742041
DOI: 10.1038/s41592-019-0326-x
|
|
4862
Yonesaka K, Kobayashi Y, Hayashi H1, Chiba Y, Mitsudomi T, Nakagawa K.
Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR‑mutant Ba/F3 cells.
Oncol Rep
2019
1(2):1059-1066
PubMed ID: 30483795
DOI: 10.3892/or.2018.6881
|
|
4865
Eguchi A, Nakakido M, Nagatoishi S, Kuroda D, Tsumoto K, Nagamune T, Kawahara M.
An epitope-directed antibody affinity maturation system utilizing mammalian cell survival as readout.
Biotechnol Bioeng
2019
116(7):1742-1751
PubMed ID: 30883677
DOI: 10.1002/bit.26965
|
|
4870
Udagawa H#1, Hasako S#2, Ohashi A, Fujioka R, Hakozaki Y, Shibuya M, Abe N, Komori T, Haruma T, Terasaka M, Fujita R, Hashimoto A, Funabashi K, Yasuda H, Miyadera K, Goto K, Costa DB, Kobayashi S.
TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.
Mol Cancer Res
2019
17(11):2233-2243
PubMed ID: 31467113
DOI: 10.1158/1541-7786.MCR-19-0419
|
|
4872
Tanaka H, Sakagami H, Kaneko N, Konagai S, Yamamoto H, Matsuya T, Yuri M, Yamanaka Y, Mori M, Takeuchi M, Koshio H, Hirano M, Kuromitsu S.
Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.
Mol Cancer Ther
2019
18(8):1366-1373
PubMed ID: 31092564
DOI: 10.1158/1535-7163.MCT-18-0976
|
|
4875
Yuki Uchiharaa, Tomoyuk iOhe, Tadahiko Mashino, Takayuki Kidokoro, Kenji Tago, Hiroomi Tamura, Megumi Funakoshi-Tago
N-Acetyl cysteine prevents activities of STAT3 inhibitors, Stattic and BP-1-102 independently of its antioxidant properties
Pharmacol Rep
2019
71(6):1067-1078
PubMed ID: 31627175
DOI: 10.1016/j.pharep.2019.05.021
|
|
11622
Fujino T, Kobayashi Y, Suda K, Koga T, Nishino M, Ohara S, Chiba M, Shimoji M, Tomizawa K, Takemoto T, Mitsudomi T.
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro.
J Thorac Oncol
2019
14(10):1753-1765
PubMed ID: 31279006
DOI: 10.1016/j.jtho.2019.06.023
|
|
6896
Kim HJ, Kim HJ, Kim MK, Bae MK, Sung HY, Ahn JH, Kim YH, Kim SC, Ju W.
SPSB1 enhances ovarian cancer cell survival by destabilizing p21.
Biochem Biophys Res Commun
2019
510(3):364-369
PubMed ID: 30712944
DOI: 10.1016/j.bbrc.2019.01.088
|
|
12393
Futami T, Kawase T, Mori K, Asaumi M, Kihara R, Shindoh N, Kuromitsu S.
Identification of a novel oncogenic mutation of FGFR4 in gastric cancer
Sci Rep
2019
9(1):14627
PubMed ID: 31601997
DOI: 10.1038/s41598-019-51217-6
|
|
12394
Kawase T, Nakazawa T, Eguchi T, Tsuzuki H, Ueno Y, Amano Y, Suzuki T, Mori M, Yoshida T.
Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells
Oncotarget
2019
10(58):6111-6123
PubMed ID: 31692922
DOI: 10.18632/oncotarget.27222
|
|
10032
Oyama S, Kitamura H, Kuramochi T, Higuchi Y, Matsushita H, Suzuki T, Goto M, Adachi H, Kasutani K, Sakamoto A, Iwayanagi Y, Kaneko A, Nanami M, Fujii E, Esaki K, Takashima Y, Shimaoka S, Hattori K, Kawabe Y.
Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody.
Exp. Dermatol.
2018
27:14-21
PubMed ID: 27714851
DOI: 10.1111/exd.13236
|
|
4160
Koga T, Kobayashi Y, Tomizawa K, Suda K, Kosaka T, Sesumi Y, Fujino T, Nishino M, Ohara S, Chiba M, Shimoji M, Takemoto T, Suzuki M, Jänne PA, Mitsudomi T.
Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.
Lung Cancer
2018
PubMed ID: 30527195
DOI: 10.1016/j.lungcan.2018.10.019
|
|
4161
Kobayashi Y, Fujino T, Nishino M, Koga T, Chiba M, Sesumi Y, Ohara S, Shimoji M, Tomizawa K, Takemoto T, Mitsudomi T.
EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib.
J Thorac Oncol
2018
PubMed ID: 29410323
DOI: 10.1016/j.jtho.2018.01.009
|
|
4162
Uchihara Y, Tago K, Taguchi H, Narukawa Y, Kiuchi F, Tamura H, Funakoshi-Tago M.
Taxodione induces apoptosis in BCR-ABL-positive cells through ROS generation.
Biochem. Pharmacol.
2018
PubMed ID: 29859988
DOI: 10.1016/j.bcp.2018.05.018
|
|
4163
Funahashi SI, Kawai S, Fujii E, Taniguchi K, Nakano K, Ishikawa S, Aburatani H, Suzuki M.
Generation of an anti-desmoglein 3 antibody without pathogenic activity of pemphigus vulgaris for therapeutic application to squamous cell carcinoma.
J. Biochem.
2018
PubMed ID: 30239818
DOI: 10.1093/jb/mvy074
|
|
4164
Yoshida H, Yamada H, Nogami W, Dohi K, Kurino-Yamada T, Sugiyama K, Takahashi K, Gahara Y, Kitaura M, Hasegawa M, Oshima I, Kuwabara K.
Development of a new knock-in mouse model and evaluation of pharmacological activities of lusutrombopag, a novel, nonpeptidyl small-molecule agonist of the human thrombopoietin receptor c-Mpl.
Exp. Hematol.
2018
PubMed ID: 29274361
DOI: 10.1016/j.exphem.2017.12.005
|
|
4269
Hirao T, Yamaguchi M, Kikuya M, Chibana H, Ito K, Aoki S.
Altered intracellular signaling by imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells.
Cancer Sci.
2018
PubMed ID: 29121435
DOI: 10.1111/cas.13442
|
|
4471
Katayama K, Noguchi K, Sugimoto Y.
Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia.
Oncotarget
2018
9(76):34240-34258
PubMed ID: 30344940
DOI: 10.18632/oncotarget.26045
|
|
15838
Hasako S, Terasaka M, Abe N, Uno T, Ohsawa H, Hashimoto A, Fujita R, Tanaka K, Okayama T, Wadhwa R, Miyadera K, Aoyagi Y, Yonekura K, Matsuo K.
TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
Mol Cancer Ther
2018
17(8):1648-1658
PubMed ID: 29748209
DOI: 10.1158/1535-7163.MCT-17-1206
|
|
10205
Nguyen TD, Takasuka H, Kaku Y, Inoue S, Nagamune T, Kawahara M.
Engineering a growth sensor to select intracellular antibodies in the cytosol of mammalian cells.
J. Biosci. Bioeng.
2017
124:125-132
PubMed ID: 28319021
DOI: 10.1016/j.jbiosc.2017.02.017
|
|
10264
Nagata N, Iwanari H, Kumagai H, Kusano-Arai O, Ikeda Y, Aritake K, Hamakubo T, Urade Y.
Generation and characterization of an antagonistic monoclonal antibody against an extracellular domain of mouse DP2 (CRTH2/GPR44) receptors for prostaglandin D2.
PLoS ONE
2017
12:e0175452
PubMed ID: 28394950
DOI: 10.1371/journal.pone.0175452
|
|
10272
Chiba M, Togashi Y, Bannno E, Kobayashi Y, Nakamura Y, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K.
Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.
BMC Cancer
2017
17:281
PubMed ID: 28424065
DOI: 10.1186/s12885-017-3263-z
|
|
4570
Funahashi SI, Suzuki Y, Nakano K, Kawai S, Suzuki M.
Generation and characterization of monoclonal antibodies against human LGR6.
J Biochem
2017
161(4):361-368
PubMed ID: 28013222
DOI: 10.1093/jb/mvw077
|
|
4842
Kim SY, Ahn T, Bang H, Ham JS, Kim J, Kim ST, Jang J, Shim M, Kang SY, Park SH, Min BH, Lee H, Kang WK, Kim KM, Park W, Lee J.
Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion.
Oncotarget
2017
8(9):15014-15022
PubMed ID: 28122360
DOI: 10.18632/oncotarget.14788
|
|
4859
Cho J, Kim SY, Kim YJ, Sim MH, Kim ST, Kim NKD, Kim K, Park W, Kim JH, Jang KT, Lee J.
Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma.
Clin Transl Oncol
2017
19(10):1247-1252
PubMed ID: 28421416
DOI: 10.1007/s12094-017-1662-x
|
|
4859
Cho J, Kim SY, Kim YJ, Sim MH, Kim ST, Kim NKD, Kim K, Park W, Kim JH, Jang KT, Lee J.
Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma.
Clin Transl Oncol
2017
19(10):1247-1252
PubMed ID: 28421416
DOI: 10.1007/s12094-017-1662-x
|
|
4873
Watanabe M, Nakano K, Kadin ME, Higashihara M, Watanabe T, Horie R.
CD30 Induces Heat Shock Protein 90 and Signal Integration in Classic Hodgkin Lymphoma Cells.
Am J Pathol
2017
187(1):163-175
PubMed ID: 27870927
DOI: 10.1016/j.ajpath.2016.09.007
|
|
4878
Uchihara Y, Ueda F, Tago K, Nakazawa Y, Ohe T, Mashino T, Yokota S, Kasahara T, Tamura H, Funakoshi-Tago M.
Alpha-tocopherol attenuates the anti-tumor activity of crizotinib against cells transformed by NPM-ALK.
PLoS One
2017
12(8):e0183003
PubMed ID: 28806414
DOI: 10.1371/journal.pone.0183003
|
|
14040
Aihara A, Koike T, Abe N, Nakamura S, Sawaguchi A, Nakamura T, Sugimoto N, Nakauchi H, Nishino T, Eto K.
Novel TPO receptor agonist TA-316 contributes to platelet biogenesis from human iPS cells
Blood Adv
2017
1(7):468-476
PubMed ID: 29296963
DOI: 10.1182/bloodadvances.2016000844
|
|
10912
Izuta S, Yamaguchi S, Misawa R, Yamahira S, Tan M, Kawahara M, Suzuki T, Takagi T, Sato K, Nakamura M, Nagamune T, Okamoto A.
Microfluidic preparation of anchored cell membrane sheets for in vitro analyses and manipulation of the cytoplasmic face
Sci Rep
2017
7(1):14962
PubMed ID: 29097751
DOI: 10.1038/s41598-017-14737-7
|
|
14690
Ogura H, Nagatake-Kobayashi Y, Adachi J, Tomonaga T, Fujita N, Katayama R.
TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity
Sci Rep
2017
7(1):5519
PubMed ID: 28717217
DOI: 10.1038/s41598-017-05736-9
|
|
17940
Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, Dagogo-Jack I, Gadgeel S, Schultz K, Singh M, Chin E, Parks M, Lee D, DiCecca RH, Lockerman E, Huynh T, Logan J, Ritterhouse LL, Le LP, Muniappan A, Digumarthy S, Channick C, Keyes C, Getz G, Dias-Santagata D, Heist RS, Lennerz J, Sequist LV, Benes CH, Iafrate AJ, Mino-Kenudson M, Engelman JA, Shaw AT.
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Cancer Discov
2016
6(10):1118-1133
PubMed ID: 27432227
DOI: 10.1158/2159-8290.CD-16-0596
|
|
4852
Miura T, Nagamune T, Kawahara M.
Ligand-inducible dimeric antibody for selecting antibodies against a membrane protein based on mammalian cell proliferation.
Biotechnol Bioeng
2016
113(5):1113-23
PubMed ID: 26479395
DOI: 10.1002/bit.25858
|
|
4860
Ishibashi T, Yaguchi A, Terada K, Ueno-Yokohata H, Tomita O, Iijima K, Kobayashi K, Okita H, Fujimura J, Ohki K, Shimizu T, Kiyokawa N.
Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.
Exp Hematol
2016
44(3):177-88.e5
PubMed ID: 26703895
DOI: 10.1016/j.exphem.2015.11.009
|
|
14140
Stevens MM, Maire CL, Chou N, Murakami MA, Knoff DS, Kikuchi Y, Kimmerling RJ, Liu H, Haidar S, Calistri NL, Cermak N, Olcum S, Cordero NA, Idbaih A, Wen PY, Weinstock DM, Ligon KL, Manalis SR.
Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate
Nat Biotechnol
2016
34(11):1161-1167
PubMed ID: 27723727
DOI: 10.1038/nbt.3697
|
|
4843
Trung LQ, Espinoza JL, An DT, Viet NH1, Shimoda K, Nakao S.
Resveratrol selectively induces apoptosis in malignant cells with the JAK2V617F mutation by inhibiting the JAK2 pathway.
Mol Nutr Food Res
2015
59(11):2143-54
PubMed ID: 26375873
DOI: 10.1002/mnfr.201500166
|
|
4849
Fujita T, Yuno M, Okuzaki D, Ohki R, Fujii H.
Identification of non-coding RNAs associated with telomeres using a combination of enChIP and RNA sequencing.
PLoS One
2015
10(4):e0123387
PubMed ID: 25874893
DOI: 10.1371/journal.pone.0123387
|
|
14974
Ota K, Azuma K, Kawahara A, Hattori S, Iwama E, Tanizaki J, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, Hoshino T, Nakanishi Y, Okamoto I.
Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer
Clin Cancer Res
2015
21(17):4014-21
PubMed ID: 26019170
DOI: 10.1158/1078-0432.CCR-15-0016
|
|
15120
Kobayashi Y, Togashi Y, Yatabe Y, Mizuuchi H, Jangchul P, Kondo C, Shimoji M, Sato K, Suda K, Tomizawa K, Takemoto T, Hida T, Nishio K, Mitsudomi T.
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
Clin Cancer Res
2015
21(23):5305-13
PubMed ID: 26206867
DOI: 10.1158/1078-0432.CCR-15-1046
|
|
15188
Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu SC, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, Gritsman K, Gotlib J, Deininger MW, Makishima H, Turley SJ, Javidi-Sharifi N, Maciejewski JP, Jaiswal S, Ebert BL, Rodig SJ, Tyner JW, Marto JA, Weinstock DM, Lane AA.
Mutations in G protein β subunits promote transformation and kinase inhibitor resistance
Nat Med
2015
21(1):71-5
PubMed ID: 25485910
DOI: 10.1038/nm.3751
|
|
4836
Tomita O, Iijima K, Ishibashi T, Osumi T, Kobayashi K, Okita H, Saito M, Mori T, Shimizu T, Kiyokawa N.
Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1.
Leuk Res
2014
38(3):361-70
PubMed ID: 24367893
DOI: 10.1016/j.leukres.2013.11.017
|
|
4839
Nakaya Y, Shide K, Naito H, Niwa T, Horio T, Miyake J, Shimoda K.
Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis.
Blood Cancer J
2014
4:e174
PubMed ID: 24413068
DOI: 10.1038/bcj.2013.73
|
|
4850
Yoshida R1, Kawahara M, Nagamune T.
A novel platform for antibody library selection in mammalian cells based on a growth signalobody.
Biotechnol Bioeng
2014
111(6):1170-9
PubMed ID: 24338724
DOI: 10.1002/bit.25173
|
|
4851
Yidan Ma, Teruyuki Nagamune, Masahiro Kawahara
Split focal adhesion kinase for probing protein–protein interactions
Biochemical Engineering Journal
2014
90:272-278
DOI: 10.1016/j.bej.2014.06.022
|
|
4857
Kawahara M, Hitomi A, Nagamune T.
Antigen-responsive regulation of Cell motility and migration via the signalobodies based on c-Fms and c-Mpl.
Biotechnol Prog
2014
30(2):411-7
PubMed ID: 24375974
DOI: 10.1002/btpr.1861
|
|
4858
Saka K, Kawahara M, Nagamune T.
Quantitative control of intracellular signaling activity through chimeric receptors incorporating multiple identical tyrosine motifs.
Biotechnol Bioeng
2014
111(5):948-55
PubMed ID: 24222636
DOI: 10.1002/bit.25151
|
|
4866
Kodama T, Tsukaguchi T, Satoh Y, Yoshida M, Watanabe Y, Kondoh O, Sakamoto H.
Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
Mol Cancer Ther
2014
13(12):2910-8
PubMed ID: 25349307
DOI: 10.1158/1535-7163.MCT-14-0274
|
|
12522
Kato A, Fujii E, Watanabe T, Takashima Y, Matsushita H, Furuhashi T, Morita A.
Distribution of IL-31 and its receptor expressing cells in skin of atopic dermatitis
J Dermatol Sci
2014
4(3):229-35
PubMed ID: 24667097
DOI: 10.1016/j.jdermsci.2014.02.009
|
|
18280
Oh B, Kim TY, Min HJ, Kim M, Kang MS, Huh JY, Kim Y, Lee DS.
Synergistic killing effect of imatinib and simvastatin on imatinib-resistant chronic myelogenous leukemia cells
Anticancer Drugs
2013
24(1):20-31
PubMed ID: 23075630
DOI: 10.1097/CAD.0b013e32835a0fbd
|
|
18602
Cox JH, Hussell S, Søndergaard H, Roepstorff K, Bui JV, Deer JR, Zhang J, Li ZG, Lamberth K, Kvist PH, Padkjær S, Haase C, Zahn S, Odegard VH.
Antibody-mediated targeting of the Orai1 calcium channel inhibits T cell function
PLoS One
2013
8(12):e82944
PubMed ID: 24376610
DOI: 10.1371/journal.pone.0082944
|
|
4838
Li SQ, Cheuk AT, Shern JF, Song YK, Hurd L, Liao H, Wei JS, Khan J.
Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).
PLoS One
2013
8(10):e76551
PubMed ID: 24124571
DOI: 10.1371/journal.pone.0076551
|
|
4841
Takagi M, Sato M, Piao J, Miyamoto S, Isoda T, Kitagawa M, Honda H, Mizutani S.
ATM-dependent DNA damage-response pathway as a determinant in chronic myelogenous leukemia.
DNA Repair (Amst)
2013
12(7):500-7
PubMed ID: 23694754
DOI: 10.1016/j.dnarep.2013.04.022
|
|
4845
Nakabayashi H, Kawahara M, Tanaka K, Nagamune T.
Construction of antibody/insulin receptor chimera for growth induction of mammalian cells.
Cytotechnology
2013
65(6):945-53
PubMed ID: 23615961
DOI: 10.1007/s10616-013-9571-5
|
|
4846
Saka K, Kawahara M, Nagamune T.
Reconstitution of a cytokine receptor scaffold utilizing multiple different tyrosine motifs.
Biotechnol Bioeng
2013
110(12):3197-204
PubMed ID: 23775041
DOI: 10.1002/bit.24973
|
|
4855
Tone Y, Kawahara M, Hayashi J, Nagamune T.
Cell fate conversion by conditionally switching the signal-transducing domain of signalobodies.
Biotechnol Bioeng
2013
110(12):3219-26
PubMed ID: 23794462
DOI: 10.1002/bit.24985
|
|
4861
Saka K, Kawahara M, Teng J, Otsu M, Nakauchi H, Nagamune T.
Top-down motif engineering of a cytokine receptor for directing ex vivo expansion of hematopoietic stem cells.
J Biotechnol
2013
168(4):659-65
PubMed ID: 24070902
DOI: 10.1016/j.jbiotec.2013.09.012
|
|
16424
Nakamura M, Uehara Y, Asada M, Suzuki M, Imamura T.
Sulfated glycosaminoglycan-assisted receptor specificity of human fibroblast growth factor (FGF) 19 signaling in a mouse system is different from that in a human system
J Biomol Screen
2013
18(3):321-30
PubMed ID: 23064887
DOI: 10.1177/1087057112463820
|
|
4837
Kaneda M1, Odaka T, Suetake H, Tahara D, Miyadai T.
Teleost IL-6 promotes antibody production through STAT3 signaling via IL-6R and gp130.
Dev Comp Immunol
2012
38(2):224-31
PubMed ID: 22469658
DOI: 10.1016/j.dci.2012.02.002
|
|
4854
Shindoh N, Yoda A, Yoda Y, Sullivan TJ, Weigert O, Lane AA, Kopp N, Bird L, Rodig SJ, Fox EA, Weinstock DM.
Next-generation cDNA screening for oncogene and resistance phenotypes.
PLoS One
2012
7(11):e49201
PubMed ID: 23145123
DOI: 10.1371/journal.pone.0049201
|
|
4880
Itonaga H, Tsushima H, Hata T, Matsuo E, Imanishi D, Imaizumi Y, Kawaguchi Y, Fukushima T, Doi Y, Mori S, Kamihira S, Tomonaga M, Miyazaki Y.
Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa.
Int J Hematol
2012
95(2):209-13
PubMed ID: 22262141
DOI: 10.1007/s12185-012-1005-1
|
|
7791
Nakamura M, Uehara Y, Asada M, Honda E, Nagai N, Kimata K, Suzuki M, Imamura T.
Sulfated glycosaminoglycans are required for specific and sensitive fibroblast growth factor (FGF) 19 signaling via FGF receptor 4 and betaKlotho.
J. Biol. Chem.
2011
286:26418-23
PubMed ID: 21653700
DOI: 10.1074/jbc.M111.251140
|
|
4844
Tsuruyama T, Hiratsuka T, Jin G, Imai Y, Takeuchi H, Maruyama Y, Kanaya K, Ozeki M, Takakuwa T, Haga H, Tamaki K, Nakamura T.
Murine leukemia retrovirus integration induces the formation of transcription factor complexes on palindromic sequences in the signal transducer and activator of transcription factor 5a gene during the development of pre-B lymphomagenesis.
Am J Pathol
2011
178(3):1374-86
PubMed ID: 21356387
DOI: 10.1016/j.ajpath.2010.12.012
|
|
15721
Shen M, Siu S, Byrd S, Edelmann KH, Patel N, Ketchem RR, Mehlin C, Arnett HA, Hasegawa H.
Diverse functions of reactive cysteines facilitate unique biosynthetic processes of aggregate-prone interleukin-31
Exp Cell Res
2011
317(7):976-93
PubMed ID: 21182835
DOI: 10.1016/j.yexcr.2010.12.012
|
|
4888
Ikezoe T, Takeuchi T, Yang J, Adachi Y, Nishioka C, Furihata M, Koeffler HP, Yokoyama A.
Analysis of Aurora B kinase in non-Hodgkin lymphoma.
Lab Invest
2009
89(12):1364-73
PubMed ID: 19823168
DOI: 10.1038/labinvest.2009.106
|
|
18169
Yamane N, Tanaka Y, Ohyabu N, Yamane S, Maekawa K, Ishizaki J, Suzuki R, Itoh T, Takemoto H.
Characterization of novel non-peptide thrombopoietin mimetics, their species specificity and the activation mechanism of the thrombopoietin receptor
Eur J Pharmacol
2008
586(1-3):44-51
PubMed ID: 18377892
DOI: 10.1016/j.ejphar.2008.02.060
|
|
4856
Asada M, Honda E, Imamura T.
Biologically active fibroblast growth factor 1 tagged with various epitopes.
BMC Res Notes
2008
1:42
PubMed ID: 18710495
DOI: 10.1186/1756-0500-1-42
|
|
4876
Takada A, Yoshida S, Kajikawa M, Miyatake Y, Tomaru U, Sakai M, Chiba H, Maenaka K, Kohda D, Fugo K, Kasahara M.
Two novel NKG2D ligands of the mouse H60 family with differential expression patterns and binding affinities to NKG2D.
J Immunol
2008
180(3):1678-85
PubMed ID: 18209064
DOI: 10.4049/jimmunol.180.3.1678
|
|
14416
Yamane N, Takahashi K, Tanaka Y, Kato K, Takayama M, Ohyabu N, Shiota T, Takenaka H, Yoshida Y, Hara S, Murashi T, Nakamura E, Nishitani Y, Ishizaki J, Yamane S, Nagata K, Koizumi K, Yutsudo T, Suzuki R, Itoh T, Takemoto H.
Discovery of novel non-peptide thrombopoietin mimetic compounds that induce megakaryocytopoiesis
Biosci Rep . 2008 Oct;28(5):275-85
2008
28(5):275-85
PubMed ID: 18620546
DOI: 10.1042/BSR20080086
|
|
16421
Motomura K, Hagiwara A, Komi-Kuramochi A, Hanyu Y, Honda E, Suzuki M, Kimura M, Oki J, Asada M, Sakaguchi N, Nakayama F, Akashi M, Imamura T.
An FGF1:FGF2 chimeric growth factor exhibits universal FGF receptor specificity, enhanced stability and augmented activity useful for epithelial proliferation and radioprotection
Biochim Biophys Acta
2008
1780(12):1432-40
PubMed ID: 18760333
DOI: 10.1016/j.bbagen.2008.08.001
|
|
2882
Maeda T, Yagasaki F, Ishikawa M, Takahashi N, Bessho M.
Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML.
Blood
2005
105(5):2115-23
PubMed ID: 15514005
DOI: 10.1182/blood-2003-12-4290
|
|
4879
Nawata R, Yujiri T, Nakamura Y, Ariyoshi K, Takahashi T, Sato Y, Oka Y, Tanizawa Y.
MEK kinase 1 mediates the antiapoptotic effect of the Bcr-Abl oncogene through NF-kappaB activation.
Oncogene
2003
22(49):7774-80
PubMed ID: 14586403
DOI: 10.1038/sj.onc.1206901
|
|
4884
Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T.
Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain
Oncogene
2002
21(16):2555-63
PubMed ID: 11971190
DOI: 10.1038/sj.onc.1205332
|
|
2559
Shimizu A, Tada K, Shukunami C, Hiraki Y, Kurokawa T, Magane N, Kurokawa-Seo M
A novel alternatively spliced fibroblast growth factor receptor 3 isoform lacking the acid box domain is expressed during chondrogenic differentiation of ATDC5 cells.
J Biol Chem
2001
276:11031-40
PubMed ID: 11134040
DOI: 10.1074/jbc.M003535200
|
|
4871
Feng R, Kabayama A, Uchida K, Hoshino H, Miwa M.
Cell-free entry of human T-cell leukemia virus type 1 to mouse cells.
Jpn J Cancer Res
2001
92(4):410-6
PubMed ID: 11346463
DOI: 10.1111/j.1349-7006.2001.tb01110.x
|
|
16915
Sun W, Hattori N, Mutai H, Toyoshima Y, Kimura H, Tanaka S, Shiota K.
PAL31, a nuclear protein required for progression to the S phase
Biochem Biophys Res Commun
2001
280(4):1048-54
PubMed ID: 11162633
DOI: 10.1006/bbrc.2000.4244
|
|
4832
Kawasaki K1, Akashi S, Shimazu R, Yoshida T, Miyake K, Nishijima M.
Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol.
J Biol Chem
2000
275(4):2251-4
PubMed ID: 10644670
DOI: 10.1074/jbc.275.4.2251
|
|
4840
Tsunekawa B, Wada M, Ikeda M, Banba S, Kamachi H, Tanaka E, Honjo M.
The binding between the stem regions of human growth hormone (GH) receptor compensates for the weaker site 1 binding of 20-kDa human GH (hGH) than that of 22-kDa hGH.
J Biol Chem
2000
275(21):15652-6
PubMed ID: 10748003
DOI: 10.1074/jbc.M001236200
|
|
4853
Odajima J, Matsumura I, Sonoyama J, Daino H, Kawasaki A, Tanaka H, Inohara N, Kitamura T, Downward J, Nakajima K, Hirano T, Kanakura Y.
Full oncogenic activities of v-Src are mediated by multiple signaling pathways. Ras as an essential mediator for cell survival.
J Biol Chem
2000
275(31):24096-105
PubMed ID: 10918073
DOI: 10.1074/jbc.m001606200
|
|
3112
Yoneda A, Asada M, Oda Y, Suzuki M, Imamura T.
Engineering of an FGF-proteoglycan fusion protein with heparin-independent, mitogenic activity.
Nat Biotechnol
2000
18(6):641-4
PubMed ID: 10835602
DOI: 10.1038/76487
|
|
4831
Kume A1, Ito K, Ueda Y, Hasegawa M, Urabe M, Mano H, Ozawa K.
A G-CSF receptor-gyrase B fusion gene: A new type of molecular switch for expansion of genetically modified hematopoietic cells.
Biochem Biophys Res Commun
1999
260(1):9-12
PubMed ID: 10381335
DOI: 10.1006/bbrc.1999.0859
|
|
4833
Matsuda KM, Kume A, Ueda Y, Urabe M, Hasegawa M, Ozawa K.
Development of a modified selective amplifier gene for hematopoietic stem cell gene therapy
Gene Ther
1999
6(6):1038-44
PubMed ID: 10455406
DOI: 10.1038/sj.gt.3300906
|
|
4834
Xu R, Kume A, Matsuda KM, Ueda Y, Kodaira H, Ogasawara Y, Urabe M, Kato I, Hasegawa M, Ozawa K.
A selective amplifier gene for tamoxifen-inducible expansion of hematopoietic cells.
J Gene Med
1999
1(4):236-44
PubMed ID: 10738556
DOI: 10.1002/(SICI)1521-2254(199907/08)1:4<236::AID-JGM42>3.0.CO;2-2
|
|
4848
Yoneda A, Asada M, Suzuki M, Imamura T.
Introduction of an N-glycosylation cassette into proteins at random sites: expression of neoglycosylated FGF.
Biotechniques
1999
27(3):576-8
PubMed ID: 10489617
DOI: 10.2144/99273rr05
|
|
2439
Tsunekawa B, Wada M, Ikeda M, Uchida H, Naito N, Honjo M.
The 20-kilodalton (kDa) human growth hormone (hGH) differs from the 22-kDa hGH in the effect on the human prolactin receptor
Endocrinology
1999
140(9):3909-18
PubMed ID: 10465259
DOI: 10.1210/endo.140.9.6959
|
|
2271
Wada M, Uchida H, Ikeda M, Tsunekawa B, Naito N, Banba S, Tanaka E, Hashimoto Y, Honjo M.
The 20-kilodalton (kDa) human growth hormone (hGH) differs from the 22-kDa hGH in the complex formation with cell surface hGH receptor and hGH-binding protein circulating in human plasma.
Mol Endocrinol
1998
2(1):146-56
PubMed ID: 9440818
DOI: 10.1210/mend.12.1.0054
|
|
18069
Chin H, Wakao H, Miyajima A, Kamiyama R, Miyasaka N, Miura O.
Erythropoietin induces tyrosine phosphorylation of the interleukin-3 receptor beta subunit (betaIL3) and recruitment of Stat5 to possible Stat5-docking sites in betaIL3
Blood
1997
89(12):4327-36
PubMed ID: 9192755
|
|
4830
Sasaki M, Sasaki T, Enami J.
Prolactin-dependent growth and gamma-casein gene expression in Ba/F3 cells transfected with a long form of mouse mammary prolactin receptor.
Endocr J
1996
43(1):45-52
PubMed ID: 8732451
DOI: 10.1507/endocrj.43.45
|
|
4883
Palaga T, Kataoka T, Woo JT, Nagai K.
Suppression of apoptotic cell death of IL-3-dependent cell lines by ER/SR Ca2+-ATPase inhibitors upon IL-3 deprivation.
Exp Cell Res
1996
228(1):92-7
PubMed ID: 8892975
DOI: 10.1006/excr.1996.0303
|
|
4835
Miyake K, Yamashita Y, Ogata M, Sudo T, Kimoto M.
RP105, a novel B cell surface molecule implicated in B cell activation, is a member of the leucine-rich repeat protein family.
J Immunol
1995
154(7):3333-40
PubMed ID: 7897216
|
戻る
細胞材料の再培養方法 (
HPS以外・
HPS )
ページトップへ
細胞材料開発室サイト